Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 17/20 | 0.61 |
| ▸ | HCRTR2 | O43614 | 17/20 | 0.61 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.38 |
| ▸ | FEN1 | P39748 | 1/20 | 0.38 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.37 |
| ▸ | CHRNA5 | P30532 | 1/20 | 0.37 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15519557 | 0.93 | HCRTR1 (0.69) | HCRTR1HCRTR2ALDH1A1 | |
| SCHEMBL15519767 | 0.87 | HCRTR1 (0.71) | HCRTR1HCRTR2 | |
| SCHEMBL15518985 | 0.85 | HCRTR1 (0.63) | HCRTR1HCRTR2 | |
| SCHEMBL15522028 | 0.80 | HCRTR2 (0.72) | HCRTR1HCRTR2 | |
| SCHEMBL15519543 | 0.79 | HCRTR1 (0.58) | HCRTR1HCRTR2 | |
| SCHEMBL15519525 | 0.79 | ALDH1A1 (0.45) | HCRTR1HCRTR2CHRNB2CHRNA5CHRNA4 | |
| SCHEMBL15520600 | 0.76 | HCRTR1 (0.60) | HCRTR1HCRTR2 | |
| SCHEMBL15327026 | 0.76 | HCRTR1 (0.50) | HCRTR1HCRTR2ALOX5APFEN1 | |
| SCHEMBL16648754 | 0.76 | HCRTR1 (1.00) | HCRTR1HCRTR2 | |
| SCHEMBL13833216 | 0.74 | ALDH1A1 (0.39) | HCRTR1HCRTR2CHRNB2CHRNA5CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140081025-A1 | HETEROAROMATIC RING DERIVATIVE | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2014-03-20 | — | — | US | disclosed |
| US-20140081025-A1 | HETEROAROMATIC RING DERIVATIVE | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2014-03-20 | — | — | US | disclosed |
| US-20140081025-A1 | HETEROAROMATIC RING DERIVATIVE | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2014-03-20 | — | — | US | disclosed |
| EP-2708537-A1 | HETEROAROMATIC RING DERIVATIVE | Taisho Pharmaceutical Co., Ltd. (JP) | 2014-03-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140081025-A1 | HETEROAROMATIC RING DERIVATIVE | HCRTR2, HCRTR1, HTT | HCRTR1 2/4885HCRTR2 1/4885ALOX5AP 2213/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.